Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | SUMO2 | P61956 | 1/20 | 0.33 |
| ▸ | SUMO1 | P63165 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP3 | Q9H4L4 | 1/20 | 0.33 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18020591 | 0.88 | CYP1A2 (0.54) | CYP1A2CYP2A6TRPV4ALDH1A1TDP1 | |
| SCHEMBL9165551 | 0.87 | ALDH1A1 (0.48) | CYP1A2CYP2A6TRPV4LDHAALDH1A1 | |
| SCHEMBL15461564 | 0.81 | CYP1A2 (0.56) | CYP1A2CYP2A6LDHAALDH1A1MAPT | |
| SCHEMBL2662857 | 0.79 | CYP1A2 (0.54) | CYP1A2CYP2A6LDHAALDH1A1HSD17B10 | |
| SCHEMBL29469846 | 0.79 | LDHA (0.62) | CYP1A2CYP2A6LDHAALDH1A1HSD17B10 | |
| SCHEMBL2649239 | 0.79 | LDHA (0.62) | CYP1A2CYP2A6LDHAALDH1A1HSD17B10 | |
| SCHEMBL11684694 | 0.79 | CYP1A2 (0.54) | CYP1A2CYP2A6LDHAALDH1A1MAPT | |
| SCHEMBL30274447 | 0.78 | CYP1A2 (0.52) | CYP1A2CYP2A6LDHAALDH1A1HSD17B10 | |
| SCHEMBL11192937 | 0.78 | CYP1A2 (0.52) | CYP1A2CYP2A6LDHAALDH1A1HSD17B10 | |
| SCHEMBL3133065 | 0.77 | CDK2 (0.46) | CYP1A2TRPV4LDHAALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110452146-A | Trifluoromethyl seleno-amino acids derivative and preparation method thereof | UNIV WUHAN TECH | 2019-11-15 | — | — | CN | claimed |
| CN-119264303-A | Pendant group functionalized fluorine-containing polymer, preparation method of fluorine-containing polymer, ion exchange membrane and application | 佛山绿动氢能科技有限公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| CN-110452146-A | Trifluoromethyl seleno-amino acids derivative and preparation method thereof | UNIV WUHAN TECH | 2019-11-15 | — | — | CN | disclosed |
| US-10000449-B2 | Bisarylsulfonamides useful in the treatment of inflammation and cancer | KANCERA AB (SE) | 2018-06-19 | — | — | US | disclosed |
| EP-2794009-B1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2017-08-30 | — | — | EP | disclosed |
| US-9718809-B2 | Bisarylsulfonamides useful in the treatment of inflammation and cancer | KANCERA AB (SE) | 2017-08-01 | — | — | US | disclosed |
| US-20160221938-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2016-08-04 | — | — | US | disclosed |
| EP-2188272-B1 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2016-02-24 | — | — | EP | disclosed |
| US-20150025068-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2015-01-22 | — | — | US | disclosed |
| WO-2004058709-A1 | CCR8 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058736-A1 | CCR8 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| US-6613942-B1 | Nonpeptide; 4-hydroxy benzoic acid hydrazides | NOVO NORDISK A/S (DK) | 2003-09-02 | — | — | US | disclosed |
| EP-1140823-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039088-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-07-06 | — | — | WO | disclosed |
| US-5707985-A | Naphthyl-, quinolyl- and isoquinolyl- sulfonamide derivatives as cell adhesion modulators | TANABE SEIYAKU CO. LTD. (JP) | 1998-01-13 | — | — | US | disclosed |
| WO-1996040641-A1 | SULFONAMIDE DERIVATIVES AS CELL ADHESION MODULATORS | TANABE SEIYAKU CO., LTD. (JP) | 1996-12-19 | — | — | WO | disclosed |
| EP-0023584-B1 | PROCESS FOR THE PREPARATION OF TRIFLUOROMETHYL NAPHTHALENES | BAYER AG (DE) | 1983-01-26 | — | — | EP | disclosed |
| US-4331613-A | Process for the preparation of trifluoromethylnaphthalenes | BAYER AKTIENGESELLSCHAFT (DE) | 1982-05-25 | — | — | US | disclosed |
| EP-0023584-A1 | Process for the preparation of trifluoromethyl naphthalenes | BAYER AG (DE) | 1981-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | CCR8, CCR1, CCR3 | CYP1A2 2414/4885CYP2A6 2280/4885TRPV4 2757/4885 |
| US-20150025068-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | NFKBIA, IL6, LITAF | CYP1A2 265/4885CYP2A6 353/4885TRPV4 3940/4885 |
| US-20160221938-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | NFKBIA, IL6, LITAF | CYP1A2 349/4885CYP2A6 398/4885TRPV4 4076/4885 |
| US-10000449-B2 | Bisarylsulfonamides useful in the treatment of inflammation and cancer | NFKBIA, IL6, LITAF | CYP1A2 349/4885CYP2A6 398/4885TRPV4 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.